Cargando...
Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of...
Guardado en:
| Publicado en: | Clin Case Rep |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412900/ https://ncbi.nlm.nih.gov/pubmed/28469859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.900 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|